- Source: Razi Cov Pars
Razi Cov Pars (Persian: رازی کوو پارس) is a COVID-19 vaccine developed by the Iranian Razi Vaccine and Serum Research Institute Razi Cov Pars is a covid-19 vaccine based on recombinant protein, which is being produced by Razi Vaccine and Serum Research Institute, Iran. This vaccine is the first injectable-intranasal recombinant protein corona vaccine.It's the second Iranian COVID-19 vaccine reaching human trials and is currently in phase III of clinical research during which it's compared to the Sinopharm BIBP vaccine.
Medical uses
It requires three doses given day 0 (intramuscular), day 21 (intramuscular) and day 51 (intranasal spray).
Pharmacology
Razi Cov Pars is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein.
Manufacturing
It's planned to produce one million doses of the vaccine each month as of September 2021.
As of 25 November 2021, 5 millions doses have been delivered to the Iranian Ministry of Health.
History
= Clinical trials
=See also
Pharmaceuticals in Iran
COVID-19 pandemic in Iran
COVID-19 vaccine clinical research
References
Further reading
Kata Kunci Pencarian:
- Razi Cov Pars
- COVID-19 vaccine
- List of COVID-19 vaccine authorizations
- Razi Vaccine and Serum Research Institute
- COVID-19
- Nasal vaccine
- COVID-19 vaccine clinical research
- Noora (vaccine)
- Healthcare in Iran
- COVID-19 pandemic in Nepal
